121 related articles for article (PubMed ID: 19148479)
21. Aberrant expression of cyclin E in low-risk node negative breast cancer.
Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML
Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.
Niméus-Malmström E; Ritz C; Edén P; Johnsson A; Ohlsson M; Strand C; Ostberg G; Fernö M; Peterson C
Eur J Cancer; 2006 Nov; 42(16):2729-37. PubMed ID: 17023159
[TBL] [Abstract][Full Text] [Related]
23. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
24. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas ML; Osterborg A; Bergkvist L; Mellstedt H
Cancer Immunol Immunother; 2009 Jan; 58(1):111-20. PubMed ID: 18488220
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.
Fjøsne HE; Jacobsen AB; Lundgren S;
Eur J Surg Oncol; 2008 Jan; 34(1):6-12. PubMed ID: 17881183
[TBL] [Abstract][Full Text] [Related]
26. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
27. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype.
Libertini SJ; Robinson BS; Dhillon NK; Glick D; George M; Dandekar S; Gregg JP; Sawai E; Mudryj M
Cancer Res; 2005 Dec; 65(23):10700-8. PubMed ID: 16322214
[TBL] [Abstract][Full Text] [Related]
28. Locoregional recurrence in breast carcinoma patients.
Yildirim E
Eur J Surg Oncol; 2009 Mar; 35(3):258-63. PubMed ID: 18644692
[TBL] [Abstract][Full Text] [Related]
29. Small interference RNA-mediated suppression of overexpressed cyclin E protein restores G1/S regulation in NIH-OVCAR-3 ovarian cancer cells.
Todd MC; Spruill SC; Meerbrey KL
Int J Oncol; 2009 Aug; 35(2):375-80. PubMed ID: 19578752
[TBL] [Abstract][Full Text] [Related]
30. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers.
Berglund P; Stighall M; Jirström K; Borgquist S; Sjölander A; Hedenfalk I; Landberg G
Cancer Res; 2005 Nov; 65(21):9727-34. PubMed ID: 16266993
[TBL] [Abstract][Full Text] [Related]
31. Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
Niméus E; Malmström J; Johnsson A; Marko-Varga G; Fernö M
J Pharm Biomed Anal; 2007 Feb; 43(3):1086-93. PubMed ID: 17085005
[TBL] [Abstract][Full Text] [Related]
32. Trial and error: prognostic gene signature study design altered.
Tuma RS
J Natl Cancer Inst; 2005 Mar; 97(5):331-3. PubMed ID: 15741565
[No Abstract] [Full Text] [Related]
33. [Evaluation of 5-fluorouracil-related genes in breast cancer to predict the effect of adjuvant therapy with CMF].
Tsunoda Y; Suzuki K; Sakamoto MA; Date Y; Sawada T; Tsunoda A; Kusano M
Gan To Kagaku Ryoho; 2009 Jan; 36(1):51-5. PubMed ID: 19151563
[TBL] [Abstract][Full Text] [Related]
34. Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.
Askmalm MS; Carstensen J; Nordenskjöld B; Olsson B; Rutqvist LE; Skoog L; Stål O
Acta Oncol; 2004; 43(3):235-44. PubMed ID: 15244246
[TBL] [Abstract][Full Text] [Related]
35. Multiple gene signatures aim to qualify risk in breast cancer.
Tuma RS
J Natl Cancer Inst; 2005 Mar; 97(5):332. PubMed ID: 15741566
[No Abstract] [Full Text] [Related]
36. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
[TBL] [Abstract][Full Text] [Related]
37. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
38. p53 expression and the result of adjuvant therapy of breast cancer.
Stål O; Stenmark Askmalm M; Wingren S; Rutqvist LE; Skoog L; Ferraud L; Sullivan S; Carstensen J; Nordenskjöld B
Acta Oncol; 1995; 34(6):767-70. PubMed ID: 7576743
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
40. [Genetic bases of the radiosensitivity of breast cancer].
Delaloge S; Marsiglia H
Cancer Radiother; 2005 Mar; 9(2):77-86. PubMed ID: 15820435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
